What You Should Know:
– SV Health Investors forms $90M Medtech Convergence Fund (MCF) focused on the increasing convergence of medical technology with software, telecommunications, and new service models to create solutions to some of the most significant health challenges.
– MCF will focus on early-stage, novel device and technology solutions that are differentiated in usability and outcomes with meaningful barriers to entry through IP, design, and clinical data.
SV Health Investors announced today that it has formed
the Medtech Convergence Fund
(MCF), a $90 million early-stage, medtech venture-capital fund. SV has
partnered with the senior members of another Boston-based VC firm, Norwich Ventures, to create this new
fund and build the portfolio. The MCF team will leverage their decades of
operating and investment experience to provide entrepreneurs with the financial
support and strategic guidance necessary for building a successful business.
Teijin will share employees with the fund to strengthen long-term collaboration aimed at the development of healthcare businesses in international markets. In addition, through participation in company incubation activities with its new partners, Teijin aims to stimulate its own research and development of medical devices and services based on novel innovation models.
Healthcare solutions comprising products, services, and digital technologies are becoming increasingly vital worldwide, including in the United States and Japan where the population is aging rapidly. The Medtech Convergence Fund, and its limited partner Teijin, are committed to providing superior products and specialized services to enhance the quality of life of patients worldwide.
Teijin Limited Sole LP of MCF
Teijin Limited
is the sole Limited Partner of the MCF. Teijin’s decision to invest in the fund
reflects the company’s vision of developing disruptive, cost-saving healthcare
solutions, which closely matches the vision of the MCF team. SV Managing
Partner Paul LaViolette remarked: “The investment thesis of MCF is timely as
the healthcare market expands the use of home-centric therapies and
preventative technologies. We are thrilled to partner with Teijin in our search
for early-stage, novel devices for the MCF portfolio.”
Medtech Convergence Fund Overview
The future of medtech resides in the shifts from intervention to prevention, invasive to non-invasive and hospitals to the home. MCF will focus on technologies that can expand patient access via telehealth or utilize monitoring technologies to otherwise extend more effective management of chronic disease to the least intensive setting and ultimately the home. The fund’s investment strategy is focused on the increasing convergence of medical technology with software, telecommunications, and new service models to create solutions to some of the most significant health challenges.
